Lisa Hines
Concepts (364)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 52 | 2024 | 2452 | 3.260 |
Why?
| | Receptors, Estrogen | 12 | 2024 | 457 | 1.610 |
Why?
| | Receptors, Progesterone | 8 | 2024 | 356 | 1.210 |
Why?
| | Genetic Predisposition to Disease | 23 | 2017 | 2363 | 1.070 |
Why?
| | Menopause | 9 | 2024 | 320 | 1.040 |
Why?
| | Case-Control Studies | 37 | 2024 | 3604 | 0.890 |
Why?
| | Polymorphism, Single Nucleotide | 21 | 2022 | 2145 | 0.800 |
Why?
| | Alcohol Drinking | 9 | 2017 | 826 | 0.710 |
Why?
| | Emigrants and Immigrants | 1 | 2023 | 157 | 0.640 |
Why?
| | Risk Factors | 39 | 2024 | 10779 | 0.610 |
Why?
| | Middle Aged | 58 | 2024 | 35875 | 0.510 |
Why?
| | Coronary Disease | 3 | 2005 | 383 | 0.500 |
Why?
| | Adenylyl Cyclases | 2 | 2006 | 60 | 0.480 |
Why?
| | Parity | 5 | 2024 | 109 | 0.460 |
Why?
| | Adult | 57 | 2024 | 40449 | 0.460 |
Why?
| | Aged | 48 | 2024 | 25913 | 0.450 |
Why?
| | Alcohol Dehydrogenase | 3 | 2005 | 16 | 0.450 |
Why?
| | Genetics | 1 | 2014 | 23 | 0.410 |
Why?
| | Female | 69 | 2024 | 78271 | 0.390 |
Why?
| | Suicide, Attempted | 1 | 2017 | 422 | 0.390 |
Why?
| | Substance-Related Disorders | 2 | 2017 | 1094 | 0.380 |
Why?
| | Science | 1 | 2014 | 56 | 0.380 |
Why?
| | Faculty | 1 | 2014 | 149 | 0.370 |
Why?
| | Students | 2 | 2017 | 663 | 0.360 |
Why?
| | Reproductive History | 2 | 2024 | 12 | 0.350 |
Why?
| | Genotype | 14 | 2016 | 1833 | 0.340 |
Why?
| | Suicidal Ideation | 1 | 2017 | 577 | 0.340 |
Why?
| | Postmenopause | 4 | 2014 | 391 | 0.340 |
Why?
| | Phenotype | 4 | 2011 | 3162 | 0.330 |
Why?
| | Energy Metabolism | 4 | 2022 | 935 | 0.330 |
Why?
| | Mental Health | 1 | 2017 | 790 | 0.320 |
Why?
| | Mammography | 2 | 2009 | 166 | 0.320 |
Why?
| | Humans | 76 | 2024 | 144759 | 0.310 |
Why?
| | Breast Feeding | 3 | 2019 | 448 | 0.310 |
Why?
| | Polymorphism, Genetic | 4 | 2014 | 612 | 0.300 |
Why?
| | Vocabulary, Controlled | 1 | 2010 | 47 | 0.300 |
Why?
| | Healthcare Disparities | 9 | 2016 | 727 | 0.300 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1313 | 0.300 |
Why?
| | Alcoholism | 4 | 2017 | 817 | 0.280 |
Why?
| | California | 3 | 2024 | 475 | 0.280 |
Why?
| | San Francisco | 4 | 2023 | 60 | 0.270 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2008 | 41 | 0.270 |
Why?
| | Sex Characteristics | 4 | 2006 | 790 | 0.270 |
Why?
| | Diet | 5 | 2015 | 1273 | 0.260 |
Why?
| | Aldehyde Oxidoreductases | 3 | 2004 | 29 | 0.260 |
Why?
| | United States | 17 | 2024 | 15966 | 0.260 |
Why?
| | Estrogen Replacement Therapy | 1 | 2008 | 144 | 0.250 |
Why?
| | Medication Therapy Management | 2 | 2024 | 73 | 0.250 |
Why?
| | Hormones | 2 | 2012 | 134 | 0.240 |
Why?
| | Mexico | 5 | 2019 | 233 | 0.230 |
Why?
| | Odds Ratio | 7 | 2018 | 1075 | 0.230 |
Why?
| | Medicare Part D | 1 | 2024 | 23 | 0.220 |
Why?
| | Lipoproteins, HDL | 1 | 2005 | 101 | 0.210 |
Why?
| | Synoviocytes | 1 | 2024 | 18 | 0.210 |
Why?
| | Menstruation | 2 | 2021 | 42 | 0.210 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2024 | 53 | 0.210 |
Why?
| | Indians, North American | 6 | 2015 | 647 | 0.210 |
Why?
| | Transforming Growth Factor beta | 3 | 2013 | 479 | 0.210 |
Why?
| | Life Style | 3 | 2015 | 479 | 0.210 |
Why?
| | Universities | 2 | 2017 | 452 | 0.190 |
Why?
| | Pharmacies | 1 | 2023 | 42 | 0.190 |
Why?
| | Mass Screening | 2 | 2009 | 1347 | 0.190 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2017 | 99 | 0.190 |
Why?
| | Pharmaceutical Services | 1 | 2023 | 78 | 0.190 |
Why?
| | Aged, 80 and over | 14 | 2024 | 8265 | 0.180 |
Why?
| | Algorithms | 2 | 2010 | 1837 | 0.180 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 32 | 0.180 |
Why?
| | Blood Platelets | 1 | 2005 | 400 | 0.180 |
Why?
| | Southwestern United States | 5 | 2015 | 95 | 0.170 |
Why?
| | Health Status Disparities | 4 | 2017 | 321 | 0.170 |
Why?
| | Genetic Association Studies | 4 | 2022 | 372 | 0.170 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2021 | 51 | 0.170 |
Why?
| | Adiposity | 2 | 2016 | 543 | 0.160 |
Why?
| | Immunohistochemistry | 1 | 2024 | 1716 | 0.160 |
Why?
| | Cholesterol, HDL | 1 | 2001 | 200 | 0.160 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2014 | 248 | 0.160 |
Why?
| | Logistic Models | 7 | 2020 | 2117 | 0.160 |
Why?
| | Menarche | 1 | 2020 | 52 | 0.150 |
Why?
| | Smoking | 3 | 2015 | 1472 | 0.150 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 319 | 0.150 |
Why?
| | Age Factors | 6 | 2018 | 3333 | 0.150 |
Why?
| | Genetic Variation | 3 | 2014 | 983 | 0.150 |
Why?
| | Staphylococcal Infections | 2 | 2014 | 388 | 0.140 |
Why?
| | Bacteremia | 1 | 2021 | 221 | 0.140 |
Why?
| | Young Adult | 12 | 2021 | 14105 | 0.140 |
Why?
| | Premenopause | 4 | 2022 | 123 | 0.140 |
Why?
| | Drug Overdose | 1 | 2022 | 370 | 0.130 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1907 | 0.130 |
Why?
| | Body Size | 2 | 2015 | 95 | 0.130 |
Why?
| | Myocardial Infarction | 2 | 2004 | 1209 | 0.130 |
Why?
| | Pregnancy | 4 | 2024 | 7190 | 0.120 |
Why?
| | Incidence | 6 | 2016 | 2879 | 0.120 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2016 | 88 | 0.120 |
Why?
| | Body Mass Index | 7 | 2015 | 2438 | 0.120 |
Why?
| | Cigarette Smoking | 1 | 2017 | 99 | 0.110 |
Why?
| | Matrix Metalloproteinases | 2 | 2013 | 98 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2015 | 292 | 0.110 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 215 | 0.110 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2014 | 17 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 3 | 2024 | 370 | 0.110 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2014 | 74 | 0.110 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1326 | 0.110 |
Why?
| | Aromatase | 1 | 2014 | 32 | 0.110 |
Why?
| | Waist Circumference | 1 | 2014 | 139 | 0.100 |
Why?
| | Selenoprotein P | 1 | 2013 | 3 | 0.100 |
Why?
| | Immunity | 1 | 2014 | 139 | 0.100 |
Why?
| | Oxidative Stress | 2 | 2013 | 1339 | 0.100 |
Why?
| | Women's Health | 3 | 2016 | 310 | 0.100 |
Why?
| | Postpartum Period | 2 | 2022 | 365 | 0.100 |
Why?
| | Models, Educational | 1 | 2014 | 89 | 0.100 |
Why?
| | Endonucleases | 1 | 2013 | 34 | 0.100 |
Why?
| | Telomere Homeostasis | 1 | 2013 | 33 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 5868 | 0.100 |
Why?
| | Tobacco Smoke Pollution | 1 | 2015 | 233 | 0.100 |
Why?
| | Social Justice | 1 | 2013 | 86 | 0.100 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2013 | 49 | 0.100 |
Why?
| | Male | 14 | 2024 | 72315 | 0.090 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2012 | 26 | 0.090 |
Why?
| | Genetics, Population | 1 | 2014 | 214 | 0.090 |
Why?
| | Schizosaccharomyces | 1 | 2014 | 94 | 0.090 |
Why?
| | Infection Control | 1 | 2014 | 172 | 0.090 |
Why?
| | Interleukins | 1 | 2014 | 248 | 0.090 |
Why?
| | C-Reactive Protein | 1 | 2014 | 416 | 0.090 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2012 | 142 | 0.090 |
Why?
| | Inflammation | 2 | 2014 | 2878 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 286 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 381 | 0.090 |
Why?
| | Prognosis | 5 | 2022 | 4282 | 0.090 |
Why?
| | Health Behavior | 1 | 2017 | 785 | 0.090 |
Why?
| | Genome | 1 | 2014 | 306 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 338 | 0.090 |
Why?
| | Risk | 4 | 2015 | 911 | 0.080 |
Why?
| | Aspirin | 1 | 2014 | 399 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1054 | 0.080 |
Why?
| | Dietary Fats | 2 | 2015 | 314 | 0.080 |
Why?
| | Perception | 1 | 2014 | 377 | 0.080 |
Why?
| | Telomerase | 1 | 2013 | 248 | 0.080 |
Why?
| | Obesity | 3 | 2016 | 3077 | 0.080 |
Why?
| | Research | 1 | 2014 | 431 | 0.080 |
Why?
| | Breast | 3 | 2017 | 158 | 0.080 |
Why?
| | Registries | 3 | 2018 | 2385 | 0.080 |
Why?
| | Telomere | 1 | 2013 | 288 | 0.080 |
Why?
| | Cross Infection | 1 | 2012 | 262 | 0.080 |
Why?
| | Risk Assessment | 4 | 2022 | 3671 | 0.080 |
Why?
| | Anxiety | 1 | 2017 | 1109 | 0.080 |
Why?
| | Mammary Glands, Human | 1 | 2010 | 67 | 0.080 |
Why?
| | RNA | 1 | 2016 | 940 | 0.080 |
Why?
| | Gene-Environment Interaction | 3 | 2015 | 180 | 0.070 |
Why?
| | Mammary Glands, Animal | 1 | 2010 | 128 | 0.070 |
Why?
| | Population Surveillance | 3 | 2018 | 485 | 0.070 |
Why?
| | Weight Gain | 1 | 2013 | 556 | 0.070 |
Why?
| | Macrophage Activation | 1 | 2010 | 193 | 0.070 |
Why?
| | Natural Language Processing | 1 | 2010 | 103 | 0.070 |
Why?
| | Transcription Factors | 2 | 2013 | 1741 | 0.070 |
Why?
| | Family Health | 1 | 2008 | 191 | 0.070 |
Why?
| | Proteomics | 2 | 2006 | 1195 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5408 | 0.070 |
Why?
| | Liver | 1 | 2016 | 1887 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 529 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1135 | 0.060 |
Why?
| | Depression | 1 | 2017 | 1558 | 0.060 |
Why?
| | Collagen | 1 | 2010 | 456 | 0.060 |
Why?
| | Homozygote | 2 | 2013 | 199 | 0.060 |
Why?
| | Eye Proteins | 1 | 2007 | 90 | 0.060 |
Why?
| | Exercise | 2 | 2017 | 2201 | 0.060 |
Why?
| | Ovarian Neoplasms | 1 | 2013 | 586 | 0.060 |
Why?
| | Neoplasm Staging | 3 | 2016 | 1462 | 0.060 |
Why?
| | O(6)-Methylguanine-DNA Methyltransferase | 1 | 2006 | 6 | 0.060 |
Why?
| | Colorado | 2 | 2014 | 4564 | 0.060 |
Why?
| | Genetic Linkage | 1 | 2006 | 273 | 0.060 |
Why?
| | Biomarkers | 3 | 2010 | 4271 | 0.060 |
Why?
| | Colorectal Neoplasms | 2 | 2006 | 845 | 0.060 |
Why?
| | Cornea | 1 | 2007 | 155 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1985 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1499 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2006 | 276 | 0.060 |
Why?
| | International Agencies | 1 | 2005 | 30 | 0.060 |
Why?
| | Lens, Crystalline | 1 | 2007 | 136 | 0.060 |
Why?
| | Patient Compliance | 1 | 2009 | 588 | 0.060 |
Why?
| | World Health Organization | 1 | 2005 | 105 | 0.060 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 1 | 2024 | 8 | 0.050 |
Why?
| | Antioxidants | 1 | 2008 | 549 | 0.050 |
Why?
| | Cataract | 1 | 2007 | 238 | 0.050 |
Why?
| | Adolescent | 6 | 2021 | 22428 | 0.050 |
Why?
| | Sex Distribution | 1 | 2005 | 386 | 0.050 |
Why?
| | Gene Frequency | 1 | 2005 | 481 | 0.050 |
Why?
| | Cause of Death | 2 | 2016 | 471 | 0.050 |
Why?
| | Retinal Dehydrogenase | 2 | 2017 | 29 | 0.050 |
Why?
| | Bacterial Typing Techniques | 2 | 2014 | 44 | 0.050 |
Why?
| | Databases, Bibliographic | 1 | 2003 | 30 | 0.050 |
Why?
| | Pneumonia, Bacterial | 1 | 2024 | 113 | 0.050 |
Why?
| | Antidepressive Agents | 1 | 2005 | 248 | 0.050 |
Why?
| | Ohio | 2 | 2014 | 145 | 0.050 |
Why?
| | Soft Tissue Neoplasms | 1 | 2024 | 127 | 0.050 |
Why?
| | Prevalence | 1 | 2010 | 2834 | 0.050 |
Why?
| | Linear Models | 1 | 2005 | 854 | 0.050 |
Why?
| | Genome-Wide Association Study | 3 | 2015 | 1406 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2155 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2022 | 39 | 0.050 |
Why?
| | Signal Transduction | 5 | 2016 | 5226 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1382 | 0.050 |
Why?
| | Antimicrobial Stewardship | 1 | 2024 | 129 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2930 | 0.050 |
Why?
| | Communicable Disease Control | 1 | 2022 | 86 | 0.040 |
Why?
| | Macrophages | 1 | 2010 | 1511 | 0.040 |
Why?
| | Homeostasis | 2 | 2016 | 640 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2583 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2006 | 2182 | 0.040 |
Why?
| | Blood Culture | 1 | 2021 | 25 | 0.040 |
Why?
| | Hemostasis | 1 | 2001 | 102 | 0.040 |
Why?
| | Patient Safety | 1 | 2024 | 347 | 0.040 |
Why?
| | Age of Onset | 2 | 2016 | 551 | 0.040 |
Why?
| | Gram-Negative Bacteria | 1 | 2021 | 81 | 0.040 |
Why?
| | Societies, Medical | 1 | 2005 | 887 | 0.040 |
Why?
| | Survivors | 2 | 2016 | 520 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2023 | 335 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 433 | 0.040 |
Why?
| | Isoenzymes | 1 | 2001 | 299 | 0.040 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 508 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 2115 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2010 | 5992 | 0.040 |
Why?
| | Survival Rate | 2 | 2014 | 2089 | 0.040 |
Why?
| | Ethanol | 1 | 2004 | 627 | 0.040 |
Why?
| | Biomedical Research | 1 | 2005 | 710 | 0.040 |
Why?
| | Pneumonia | 1 | 2024 | 631 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1325 | 0.040 |
Why?
| | Regression Analysis | 1 | 2001 | 1003 | 0.030 |
Why?
| | Computational Biology | 1 | 2003 | 680 | 0.030 |
Why?
| | Genomics | 1 | 2003 | 834 | 0.030 |
Why?
| | Animals | 5 | 2016 | 38058 | 0.030 |
Why?
| | Cohort Studies | 2 | 2022 | 5960 | 0.030 |
Why?
| | Utah | 1 | 2017 | 81 | 0.030 |
Why?
| | Lipids | 1 | 2001 | 710 | 0.030 |
Why?
| | Rats, Inbred SHR | 1 | 2016 | 37 | 0.030 |
Why?
| | Lod Score | 1 | 2016 | 62 | 0.030 |
Why?
| | Gene Ontology | 1 | 2016 | 53 | 0.030 |
Why?
| | Poultry | 1 | 2016 | 11 | 0.030 |
Why?
| | Neuropeptide Y | 1 | 2016 | 10 | 0.030 |
Why?
| | Cholecystokinin | 1 | 2016 | 15 | 0.030 |
Why?
| | Receptors, Ghrelin | 1 | 2016 | 7 | 0.030 |
Why?
| | Red Meat | 1 | 2016 | 17 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 330 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2016 | 25 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 246 | 0.030 |
Why?
| | SEER Program | 1 | 2016 | 224 | 0.030 |
Why?
| | Survival | 1 | 2015 | 38 | 0.030 |
Why?
| | Mice | 3 | 2010 | 18339 | 0.030 |
Why?
| | Fishes | 1 | 2016 | 108 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Phosphatases | 1 | 2015 | 1 | 0.030 |
Why?
| | MAP Kinase Kinase Kinase 2 | 1 | 2015 | 12 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2015 | 14 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 14 | 1 | 2015 | 7 | 0.030 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2015 | 10 | 0.030 |
Why?
| | Meat | 1 | 2016 | 93 | 0.030 |
Why?
| | Immune System | 1 | 2016 | 179 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2014 | 12 | 0.030 |
Why?
| | Population Groups | 1 | 2015 | 58 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 614 | 0.030 |
Why?
| | Dietary Fiber | 1 | 2015 | 59 | 0.030 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 70 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2014 | 20 | 0.030 |
Why?
| | Janus Kinase 2 | 1 | 2014 | 29 | 0.030 |
Why?
| | Prospective Studies | 2 | 2013 | 7990 | 0.030 |
Why?
| | Janus Kinase 1 | 1 | 2014 | 26 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2014 | 23 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 68 | 0.030 |
Why?
| | Interviews as Topic | 2 | 2008 | 901 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 175 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2014 | 73 | 0.030 |
Why?
| | Hospitalization | 1 | 2024 | 2433 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2016 | 374 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2014 | 117 | 0.030 |
Why?
| | Genes, sis | 1 | 2013 | 1 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 442 | 0.030 |
Why?
| | Hospitals, Community | 1 | 2014 | 65 | 0.030 |
Why?
| | Fibroblast Growth Factor 1 | 1 | 2013 | 13 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1694 | 0.030 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2013 | 28 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1143 | 0.030 |
Why?
| | Genes, erbB-2 | 1 | 2013 | 33 | 0.020 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2013 | 22 | 0.020 |
Why?
| | Matrix Metalloproteinase 3 | 1 | 2013 | 27 | 0.020 |
Why?
| | Folic Acid | 1 | 2015 | 199 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 85 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2013 | 163 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2013 | 56 | 0.020 |
Why?
| | Nerve Growth Factors | 1 | 2013 | 78 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2013 | 162 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2013 | 93 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 74 | 0.020 |
Why?
| | Drug Interactions | 1 | 2014 | 398 | 0.020 |
Why?
| | Peroxidase | 1 | 2013 | 168 | 0.020 |
Why?
| | Platinum | 1 | 2013 | 50 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 171 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2014 | 348 | 0.020 |
Why?
| | Arizona | 1 | 2013 | 81 | 0.020 |
Why?
| | Molecular Typing | 1 | 2012 | 21 | 0.020 |
Why?
| | New Mexico | 1 | 2013 | 99 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 132 | 0.020 |
Why?
| | Genomic Instability | 1 | 2013 | 66 | 0.020 |
Why?
| | Heterozygote | 1 | 2013 | 315 | 0.020 |
Why?
| | Energy Intake | 1 | 2015 | 499 | 0.020 |
Why?
| | Catheterization | 1 | 2012 | 183 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2015 | 439 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2014 | 453 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 297 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 769 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 490 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2014 | 547 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 557 | 0.020 |
Why?
| | Alleles | 1 | 2013 | 879 | 0.020 |
Why?
| | Cell Movement | 2 | 2006 | 965 | 0.020 |
Why?
| | Weaning | 1 | 2010 | 46 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 1045 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2015 | 6048 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2947 | 0.020 |
Why?
| | Species Specificity | 1 | 2010 | 574 | 0.020 |
Why?
| | Tocopherols | 1 | 2008 | 30 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 976 | 0.020 |
Why?
| | Carotenoids | 1 | 2008 | 48 | 0.020 |
Why?
| | Vitamin A | 1 | 2008 | 59 | 0.020 |
Why?
| | Diet Records | 1 | 2008 | 85 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2012 | 462 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 333 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 881 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2012 | 708 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2008 | 293 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2008 | 180 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7173 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 159 | 0.010 |
Why?
| | Attitude to Health | 1 | 2009 | 436 | 0.010 |
Why?
| | Disease Progression | 1 | 2013 | 2847 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 2010 | 553 | 0.010 |
Why?
| | Glutathione | 1 | 2007 | 375 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 388 | 0.010 |
Why?
| | Mood Disorders | 1 | 2005 | 140 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2527 | 0.010 |
Why?
| | Receptors, Estradiol | 1 | 2003 | 2 | 0.010 |
Why?
| | Software Validation | 1 | 2003 | 9 | 0.010 |
Why?
| | Motor Activity | 1 | 2008 | 721 | 0.010 |
Why?
| | MEDLINE | 1 | 2003 | 20 | 0.010 |
Why?
| | Forecasting | 1 | 2005 | 391 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 1087 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2003 | 84 | 0.010 |
Why?
| | Disease | 1 | 2003 | 98 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 919 | 0.010 |
Why?
| | Databases, Genetic | 1 | 2003 | 248 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2003 | 521 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2006 | 1095 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2003 | 372 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 758 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 2029 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5597 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2009 | 1414 | 0.010 |
Why?
| | Bipolar Disorder | 1 | 2003 | 280 | 0.010 |
Why?
| | Comorbidity | 1 | 2005 | 1658 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2007 | 3121 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1782 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1490 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 3540 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2004 | 1125 | 0.010 |
Why?
| | Aging | 1 | 2007 | 1966 | 0.010 |
Why?
| | Hypertension | 1 | 2003 | 1263 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2003 | 1169 | 0.010 |
Why?
|
|
Hines's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|